01.11.2018
Research Networks
$758,772.00
24 months
Genomic mechanisms for loss of response to anti-TNF and anti-integrin therapy: Towards a precision medicine approach
Response to biologic therapies remains highly unpredictable during CD and UC. Therefore, this study aims to identify specific markers of response to therapy that will offer new tools for a tailored precision medicine approach for management of CD and UC, successfully matching patients to therapeutic classes most likely to be of benefit.